Targeted Delivery and Personalized Release of Therapeutic Compounds using Amphiphilic Polymers
Legal Citation
Summary of the Inventive Concept
A next-generation system for targeted delivery and controlled release of therapeutic compounds using biodegradable, amphiphilic polymers that respond to specific physiological stimuli, genetic or epigenetic profiles, or other biological signals, enabling personalized medicine and improved treatment outcomes.
Background and Problem Solved
The original patent disclosed cationic amphiphilic polymers for codelivery of hydrophobic agents and nucleic acids. However, these polymers have limitations in terms of targeted delivery, controlled release, and adaptability to individual patients' needs. The new inventive concept addresses these limitations by introducing a paradigm shift in the design of amphiphilic polymers and their applications in personalized medicine.
Detailed Description of the Inventive Concept
The new inventive concept comprises a biodegradable, amphiphilic polymer matrix that can encapsulate multiple therapeutic compounds. The polymer matrix is designed to respond to specific physiological stimuli, such as pH, temperature, or enzymatic activity, to release the therapeutic compounds in a controlled manner. The system can be tailored to target specific tissues, cells, or biological signals, enabling personalized medicine. The new claims envision a range of applications, including targeted delivery of therapeutic compounds, co-delivery of multiple agents, controlled release devices, and personalized medicine systems.
Novelty and Inventive Step
The new inventive concept introduces a novel combination of biodegradable, amphiphilic polymers and responsive release mechanisms that are tailored to individual patients' needs. The use of physiological stimuli, genetic or epigenetic profiles, or other biological signals to trigger the release of therapeutic compounds is a significant departure from the original patent's codelivery approach. The new claims provide a more sophisticated and adaptive approach to targeted delivery and controlled release of therapeutic compounds.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different types of polymers, such as anionic or zwitterionic polymers, or the incorporation of additional functionalities, such as imaging agents or sensors. Variations of the system could include the use of different release mechanisms, such as enzymatic degradation or light-responsive polymers, or the integration of machine learning algorithms to optimize the release of therapeutic compounds based on individual patients' profiles.
Potential Commercial Applications and Market
The new inventive concept has significant commercial potential in the fields of personalized medicine, targeted drug delivery, and biotechnology. The system could be used to develop novel therapeutic products and devices for a range of diseases, including cancer, genetic disorders, and infectious diseases. The market for targeted drug delivery systems is expected to grow significantly in the coming years, driven by the increasing demand for personalized medicine and more effective treatment outcomes.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/58 |
| A | A61 | A61K9/1075 |
| A | A61 | A61K31/65 |
| A | A61 | A61K47/549 |
| C | C12 | C12N15/113 |
| C | C12 | C12N2310/14 |
| C | C12 | C12N2310/351 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical drug delivery systems, polymer chemistry, and nanomedicine, with expertise in designing polymeric carriers for therapeutic compounds, particularly focusing on cationic amphiphilic polymers for co-delivery of hydrophobic and nucleic acid agents
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in chemical engineering, polymer science, or biomedical engineering, possessing knowledge of polymer synthesis, drug delivery mechanisms, and nanotechnology, with experience in designing responsive polymer matrices for targeted therapeutic delivery
Obviousness Rationale
A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's core technology of cationic amphiphilic polymers for drug delivery. The disclosed responsive release mechanisms and personalized targeting are logical progressions of existing drug delivery strategies, utilizing known polymer modification techniques and established principles of stimuli-responsive materials. The fundamental concept of tailoring polymer matrices for selective compound delivery is inherently suggested by the source patent's co-delivery approach.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,634 |
|---|---|
| Title | Cationic amphiphilic polymers for codelivery of hydrophobic agents and nucleic acids |
| Assignee(s) | UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |